Recruiting
I-DXd, R-DXd
Phase 2 Lung Cancer
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Trial #: NCT06780085
Learn More
Recruiting
HER3-DXd
Phase 2 Lung Cancer
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Trial #: NCT06731907
Learn More
Recruiting
R-DXd
Phase 1 Phase 2 Lung Cancer
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Trial #: NCT04938817
Learn More
Recruiting
I-DXd
Phase 1 Phase 2 Lung Cancer
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Trial #: NCT06780137
Learn More
Recruiting
Dato-DXd
Phase 3 Lung Cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Trial #: NCT05215340
Learn More
Recruiting
Quizartinib
Phase 3 Hematology
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Trial #: NCT06578247
Learn More
Recruiting
Dato-DXd
Phase 3 Lung Cancer
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Trial #: NCT06357533
Learn More
Recruiting
T-DXd
Phase 3 Lung Cancer
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
Trial #: NCT05048797
Learn More
Not yet recruiting
Other/Multi
Breast Cancer
Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
Trial #: NCT07092254
Learn More
Recruiting
T-DXd
Phase 2 Tumor-agnostic
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Trial #: NCT04482309
Learn More
Pages: 1  2  3  4  5  6  7  

The content contained is taken is taken directly from public registry ClinicalTrials.gov and has not been edited.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Connect with an MSL
Linkedin Icon Twitter Icon

©2024 Daiichi Sankyo, Inc. All Rights Reserved. The information provided in this site is intended for U.S. healthcare professionals only. The compounds discussed herein may have different product labeling in different countries.

MED-US-GOA-00007 06/24

TERMS & CONDITIONS PRIVACY NOTICE CONTACT US

MED-US-GOA-00007 06/24